<?xml version="1.0" encoding="UTF-8"?>
<ListRecords>
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
  <dc:title>Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication : a study with risperidone lonn-acting injection</dc:title>
  <dc:creator>EMSLEY, Robin</dc:creator>
  <dc:creator>OOSTHUIZEN, Petrus</dc:creator>
  <dc:creator>KOEN, Liezl</dc:creator>
  <dc:creator>NIEHAUS, Dana J. H</dc:creator>
  <dc:creator>MEDORI, Rossella</dc:creator>
  <dc:creator>RABINOWITZ, Jonathan</dc:creator>
  <dc:relation>International clinical psychopharmacology -- Int. clin. psychopharmacol, ISSN 0268-1315, Vol. 23 (6) , pp. 325-331</dc:relation>
  <dc:date>2008</dc:date>
  <dc:type>Text</dc:type>
  <dc:type>Article</dc:type>
  <dc:language>English</dc:language>
  <dc:publisher>Lippincott Williams &amp; Wilkins</dc:publisher>
  <dc:format>print</dc:format>
  <dc:format>7 p. ; 3/4 p</dc:format>
  <dc:subject xml:lang="fr">Antagoniste dopamine</dc:subject>
  <dc:subject xml:lang="fr">Antagoniste sérotonine</dc:subject>
  <dc:subject xml:lang="fr">Benzisoxazole dérivé</dc:subject>
  <dc:subject xml:lang="fr">Forme pharmaceutique</dc:subject>
  <dc:subject xml:lang="fr">Psychose</dc:subject>
  <dc:subject xml:lang="fr">Récepteur dopaminergique D2</dc:subject>
  <dc:subject xml:lang="fr">Récepteur sérotoninergique</dc:subject>
  <dc:subject xml:lang="fr">Traitement</dc:subject>
  <dc:subject xml:lang="fr">Antipsychotique atypique</dc:subject>
  <dc:subject xml:lang="fr">Forme libération contrôlée</dc:subject>
  <dc:subject xml:lang="fr">Homme</dc:subject>
  <dc:subject xml:lang="fr">Médicament</dc:subject>
  <dc:subject xml:lang="fr">Neuroleptique</dc:subject>
  <dc:subject xml:lang="fr">Pharmacothérapie</dc:subject>
  <dc:subject xml:lang="fr">Premier épisode</dc:subject>
  <dc:subject xml:lang="fr">Psychotrope</dc:subject>
  <dc:subject xml:lang="fr">Rispéridone</dc:subject>
  <dc:subject xml:lang="fr">Rémission</dc:subject>
  <dc:subject xml:lang="fr">Schizophrénie</dc:subject>
  <dc:subject xml:lang="en">Dopamine antagonist</dc:subject>
  <dc:subject xml:lang="en">Serotonin antagonist</dc:subject>
  <dc:subject xml:lang="en">Benzisoxazole derivatives</dc:subject>
  <dc:subject xml:lang="en">Dosage form</dc:subject>
  <dc:subject xml:lang="en">Psychosis</dc:subject>
  <dc:subject xml:lang="en">D2 Dopamine receptor</dc:subject>
  <dc:subject xml:lang="en">Serotonine receptor</dc:subject>
  <dc:subject xml:lang="en">Treatment</dc:subject>
  <dc:subject xml:lang="en">Atypical antipsychotic</dc:subject>
  <dc:subject xml:lang="en">Controlled release form</dc:subject>
  <dc:subject xml:lang="en">Human</dc:subject>
  <dc:subject xml:lang="en">Drug</dc:subject>
  <dc:subject xml:lang="en">Neuroleptic</dc:subject>
  <dc:subject xml:lang="en">Pharmacotherapy</dc:subject>
  <dc:subject xml:lang="en">First episode</dc:subject>
  <dc:subject xml:lang="en">Psychotropic</dc:subject>
  <dc:subject xml:lang="en">Risperidone</dc:subject>
  <dc:subject xml:lang="en">Remission</dc:subject>
  <dc:subject xml:lang="en">Schizophrenia</dc:subject>
  <dc:subject xml:lang="en">long-acting injectable</dc:subject>
  <dc:subject xml:lang="en">remission</dc:subject>
  <dc:subject xml:lang="en">risperidone</dc:subject>
  <dc:subject xml:lang="en">schizophrenia</dc:subject>
  <dc:subject xml:lang="es">Antagonista dopamina</dc:subject>
  <dc:subject xml:lang="es">Antagonista serotonina</dc:subject>
  <dc:subject xml:lang="es">Benzisoxazol derivado</dc:subject>
  <dc:subject xml:lang="es">Forma farmacéutica</dc:subject>
  <dc:subject xml:lang="es">Psicosis</dc:subject>
  <dc:subject xml:lang="es">Receptor dopaminérgico D2</dc:subject>
  <dc:subject xml:lang="es">Receptor serotoninérgico</dc:subject>
  <dc:subject xml:lang="es">Tratamiento</dc:subject>
  <dc:subject xml:lang="es">Antipsicótico atípico</dc:subject>
  <dc:subject xml:lang="es">Forma liberación controlada</dc:subject>
  <dc:subject xml:lang="es">Hombre</dc:subject>
  <dc:subject xml:lang="es">Medicamento</dc:subject>
  <dc:subject xml:lang="es">Neuroléptico</dc:subject>
  <dc:subject xml:lang="es">Farmacoterapia</dc:subject>
  <dc:subject xml:lang="es">Primer episodio</dc:subject>
  <dc:subject xml:lang="es">Psicotropo</dc:subject>
  <dc:subject xml:lang="es">Risperidona</dc:subject>
  <dc:subject xml:lang="es">Remisión</dc:subject>
  <dc:subject xml:lang="es">Esquizofrenia</dc:subject>
  <dc:subject>002B02B03: Psycholeptiques: tranquillisant, neuroleptique. / Psycholeptics: tranquillizer, neuroleptic.</dc:subject>
  <dc:subject>002B18C06A: Schizophrénie / Schizophrenia</dc:subject>
  <dc:subject>770-D: PSYCHOPATHOLOGIE. PSYCHIATRIE / Psychopathology. Psychiatry</dc:subject>
  <dc:subject>770-D03F01: Schizophrénie / Schizophrenia</dc:subject>
  <dc:subject>770-E: Psychopharmacologie / Psychopharmacology</dc:subject>
  <dc:subject>770-E03: Psycholeptiques: tranquillisant, neuroleptique… / Psycholeptics: tranquillizer, neuroleptic…</dc:subject>
  <dc:rights>Inist-CNRS</dc:rights>
  <dc:identifier>Inist-CNRS record number 20780505</dc:identifier>
  <dc:rights>Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS</dc:rights>
</metadata>
</ListRecords>